These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32176754)

  • 1. Liver transplantation for hepatocellular carcinoma after down staging with sorafenib: a monocentric case-matched series.
    Palen A; Grégoire E; Chopinet S; Borentain P; Gerolami R; Hardwigsen J
    J Gastrointestin Liver Dis; 2020 Mar; 29(1):120-121. PubMed ID: 32176754
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation.
    Kim BH; Park JW
    J Korean Med Sci; 2018 Nov; 33(45):e286. PubMed ID: 30402051
    [No Abstract]   [Full Text] [Related]  

  • 3. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence.
    Kang SH; Cho H; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yi NJ; Lee KW; Suh KS; Yoon JH
    J Korean Med Sci; 2018 Nov; 33(45):e283. PubMed ID: 30402048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.
    Labeur TA; Berhane S; Edeline J; Blanc JF; Bettinger D; Meyer T; Van Vugt JLA; Ten Cate DWG; De Man RA; Eskens FALM; Cucchetti A; Bonnett LJ; Van Delden OM; Klümpen HJ; Takkenberg RB; Johnson PJ
    Liver Int; 2020 Jan; 40(1):215-228. PubMed ID: 31579990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatobiliary and Pancreatic: Hepatocellular carcinoma developed with angiomyolipoma.
    Miyata T; Yamashita Y; Yamao T; Umezaki N; Tsukamoto M; Kitano Y; Yamamura K; Arima K; Kaida T; Nakagawa S; Imai K; Hashimoto D; Chikamoto A; Ishiko T; Asato T; Mikami Y; Aishima S; Baba H
    J Gastroenterol Hepatol; 2017 Mar; 32(3):547. PubMed ID: 28320064
    [No Abstract]   [Full Text] [Related]  

  • 9. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
    Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
    Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Regression of Recurrent Advanced Hepatocellular Carcinoma After Liver Transplantation in Response to Sorafenib Treatment: A Case Report.
    Lee HY; Yang KH; Choi BH; Park YM; Yoon KT; Ryu JH; Chu CW
    Transplant Proc; 2016; 48(1):247-50. PubMed ID: 26915876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
    Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
    Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for hepatocellular carcinoma: one center's experience, 1987-1994.
    Dick D; Regenstein F; Blazek J; Farr G
    J Transpl Coord; 1996 Sep; 6(3):145-7. PubMed ID: 9188373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria?
    Kumar A
    Hepatology; 2020 Oct; 72(4):1499. PubMed ID: 32319691
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of HCC: the role of liver resection in the era of transplantation.
    De Carlis L; Giacomoni A; Pirotta V; Lauterio A; Slim AO; Bondinara GF; Cardillo M; Scalamogna M; Forti D
    Transplant Proc; 2001; 33(1-2):1453-6. PubMed ID: 11267370
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG
    Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma.
    Smith AD; Dunk AA; Tuttle-Newhall JE; Trotter JF
    Lancet; 2004 Mar; 363(9412):898-9. PubMed ID: 15031047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.